Australia markets closed

GOOG Nov 2024 95.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
94.300.00 (0.00%)
As of 12:53PM EDT. Market open.
Full screen
Previous close94.30
Open94.30
Bid92.10
Ask96.00
Strike95.00
Expiry date2024-11-15
Day's range94.30 - 94.30
Contract rangeN/A
Volume6
Open interest7
  • Yahoo Finance Video

    Why Elon Musk's xAI is leagues ahead in the 'physical space'

    Elon Musk's xAI recently ended talks with Oracle (ORCL) for a potential $10 billion server deal to build out its infrastructure. As AI competition from Big Tech names like Alphabet (GOOG, GOOGL) and Microsoft (MSFT) heat up, can Musk's new company keep up or will it eclipse them entirely? Deepwater Asset Management managing partner Doug Clinton joins Asking for a Trend to discuss why he is invested in xAI and believes Musk has an interesting point of view when it comes to advocating for new tech ideas, like artificial intelligence. "I think you have to really have a deep respect for figuring out... the sciences, figuring out physics. And if you think about who in the world has done the most to figure out things, physical problems like we just talked about, it's Tesla, it's SpaceX, and it's Elon. And so I think he's probably in a different and more unique position than some of these other companies, like a Google, like an OpenAI, who are great in the digital space, but they're sort of amateurs in the physical space. I think that's where the real opportunity is for xAI." For more expert insight and the latest market action, click here to watch this full episode of Asking for a Trend. This post was written by Nicholas Jacobino

  • Investor's Business Daily

    AI Is Fueling A 'Nuclear Renaissance.' Bill Gates And Jeff Bezos Are In The Mix.

    Artificial intelligence has investors buzzing about new nuclear power plants. Sam Altman, Bill Gates and Jeff Bezos all play a role.

  • Zacks

    Amazon (AMZN) Expands AWS Clientele With Exscientia Deal

    Amazon's (AMZN) AWS partners with Exscientia to power the latter's platform for end-toend drug discovery and automation.